Gilead Sciences (GILD) Cost of Revenue (2009 - 2026)

Gilead Sciences (GILD) has reported Cost of Revenue for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.4 billion, down 6.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 billion (down 1.6% YoY), and the FY2025 annual result was $6.2 billion, changed 0.27% from the prior year.
• Cost of Revenue was $1.4 billion for Q1 2026 at Gilead Sciences, down from $1.6 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.1 billion in Q4 2023 and troughed at $1.4 billion in Q3 2022.
• Average Cost of Revenue over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2025.
• Year-over-year, Cost of Revenue slumped 46.86% in 2022 and soared 49.71% in 2023.
• Over 5 years, Cost of Revenue stood at $1.4 billion in 2022, then jumped by 49.71% to $2.1 billion in 2023, then dropped by 24.35% to $1.6 billion in 2024, then rose by 2.72% to $1.6 billion in 2025, then decreased by 11.02% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $1.4 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.